MDNA - Medicenna Therapeutics: Treating Cancer With Immunomodulators

• Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells.
• Medicenna’s candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial.
• MDNA11, an IL-2 super-agonist, has promising preclinical data and is currently under phase I trial with initial data expected by the end of Q4 2021 and an initial efficacy readout.
• Interest in the IL-2 field is growing, with well-established pharmaceutical companies acquiring emerging IL-2 focused immunotherapy companies in multi-billion dollar deals.

For further details see: